Literature DB >> 7925301

Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity.

P Dobrzanski1, R P Ryseck, R Bravo.   

Abstract

The Rel-NF-kappa B family of transcription factors plays a crucial role in the regulation of genes involved in inflammatory and immune responses. We demonstrate that in vivo, in contrast to the other members of the family, RelB associates efficiently only with NF-kappa B1 (p105-p50) and NF-kappa B2 (p100-p52), but not with cRel or p65. The RelB-p52 heterodimers display a much lower affinity for I kappa B alpha than RelB-p50 heterodimers or p65 complexes. However, similarly to the other Rel-NF-kappa B complexes, RelB-p52 can upregulate the synthesis of I kappa B alpha leading to the cytoplasmic trapping of dimers which have a higher affinity for the inhibitor. We suggest that a hierarchy of interactions between I kappa B alpha and the different Rel-NF-kappa B complexes governs their cellular distribution. This results in the presence of two distinct pools of NF-kappa B activity which differ in their composition: one a constitutive nuclear and the other an inducible cytoplasmic activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925301      PMCID: PMC395393          DOI: 10.1002/j.1460-2075.1994.tb06782.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  62 in total

1.  The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.

Authors:  M Kieran; V Blank; F Logeat; J Vandekerckhove; F Lottspeich; O Le Bail; M B Urban; P Kourilsky; P A Baeuerle; A Israël
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

Review 2.  The inducible transcription activator NF-kappa B: regulation by distinct protein subunits.

Authors:  P A Baeuerle
Journal:  Biochim Biophys Acta       Date:  1991-04-16

3.  The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control.

Authors:  H Ohno; G Takimoto; T W McKeithan
Journal:  Cell       Date:  1990-03-23       Impact factor: 41.582

4.  Molecular and biochemical characterization of the human trk proto-oncogene.

Authors:  D Martin-Zanca; R Oskam; G Mitra; T Copeland; M Barbacid
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

Review 5.  Nuclear receptors enhance our understanding of transcription regulation.

Authors:  S Green; P Chambon
Journal:  Trends Genet       Date:  1988-11       Impact factor: 11.639

6.  The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Authors:  D W Ballard; W H Walker; S Doerre; P Sista; J A Molitor; E P Dixon; N J Peffer; M Hannink; W C Greene
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

7.  Evidence for differential functions of the p50 and p65 subunits of NF-kappa B with a cell adhesion model.

Authors:  R Narayanan; K A Higgins; J R Perez; T A Coleman; C A Rosen
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

8.  Expression of different Jun and Fos proteins during the G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations.

Authors:  K Kovary; R Bravo
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  33 in total

Review 1.  NFκB function and regulation in cutaneous T-cell lymphoma.

Authors:  Tzu-Pei Chang; Ivana Vancurova
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

2.  Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB.

Authors:  K Kalli; C Huntoon; M Bell; D J McKean
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 3.  The NF-kappaB family of transcription factors and its regulation.

Authors:  Andrea Oeckinghaus; Sankar Ghosh
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10       Impact factor: 10.005

4.  Celebrating 25 years of NF-κB research.

Authors:  Sankar Ghosh; Matthew S Hayden
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

5.  The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells.

Authors:  M Jamaluddin; A Casola; R P Garofalo; Y Han; T Elliott; P L Ogra; A R Brasier
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  The nfkb1 promoter is controlled by proteins of the Ets family.

Authors:  P F Lambert; M J Ludford-Menting; N J Deacon; I Kola; R R Doherty
Journal:  Mol Biol Cell       Date:  1997-02       Impact factor: 4.138

7.  Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences.

Authors:  J C Betts; G J Nabel
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

Review 8.  Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Mediators Inflamm       Date:  2010-04-12       Impact factor: 4.711

9.  Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2.

Authors:  Dietrich B Conze; Yongge Zhao; Jonathan D Ashwell
Journal:  PLoS Biol       Date:  2010-10-26       Impact factor: 8.029

10.  Evidence for the involvement of a nuclear NF-kappa B inhibitor in global down-regulation of the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells.

Authors:  X Liu; R Ge; R P Ricciardi
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.